Surface Oncology (DB:QSOA) - Prezzo delle azioni, notizie e analisi

QSOA Panoramica delle azioni

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. Maggiori dettagli

QSOA analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Ha meno di 1 anno di pista di cassa

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati diluiti nell'ultimo anno

+ 2 più rischi

Surface Oncology, Inc. Concorrenti

4SC

DB:VSC

€51.9m

Medigene

XTRA:MDG1

€20.6m

Heidelberg Pharma

XTRA:HPHA

€106.7m

2invest

XTRA:2INV

€63.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Surface Oncology
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.99
Massimo di 52 settimane	US$1.41
Minimo di 52 settimane	US$0.52
Beta	1.75
1Variazione di 1 mese	16.19%
Variazione a 3 mesi	36.16%
Variazione di 1 anno	-27.10%
3Variazione a 3 anni	-82.41%
Variazione a 5 anni	-88.77%
Variazione dall'IPO	-90.74%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	QSOA	DE Biotechs	DE Mercato
7D	-0.7%	0.8%	0.8%
1Y	-27.1%	-18.3%	8.6%

Ritorno vs Industria: QSOA ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -18.3 % nell'ultimo anno.

Rendimento vs Mercato: QSOA ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.6 % nell'ultimo anno.

Volatilità dei prezzi

Is QSOA's price volatile compared to industry and market?
QSOA volatility
QSOA Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di QSOA è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 12% ) di QSOA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	35	Rob Ross	www.surfaceoncology.com

Surface Oncology, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Surface Oncology con la sua capitalizzazione di mercato?
QSOA statistiche fondamentali
Capitalizzazione di mercato	€60.83m
Guadagni(TTM)	-€86.46m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.7x

Rapporto P/E

QSOA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
QSOA Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$67.00m
Profitto lordo	-US$67.00m
Altre spese	US$25.50m
Guadagni	-US$92.50m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.52
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato QSOA nel lungo periodo?

Vedi performance storica e confronto

QSOA Panoramica delle azioni

Analisi del rischio

Surface Oncology, Inc. Concorrenti

DB:VSC

€51.9m

XTRA:MDG1

€20.6m

XTRA:HPHA

€106.7m

XTRA:2INV

€63.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Recent updates

Surface Oncology, Inc. Files Form 15

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Full year 2022 earnings released: US$1.14 loss per share (vs US$1.77 loss in FY 2021)

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.43 loss in 2Q 2021)

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

First quarter 2022 earnings released: EPS: US$0.13 (vs US$0.37 loss in 1Q 2021)

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

Revenue beats expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

New 90-day low: €5.95

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

New 90-day high: €9.20

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

New 90-day high: €8.75

Surface Oncology, Inc. Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer

Revenue in line with expectations

Surface Oncology to Present Srf388 and Srf114 Preclinical Data At the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference

Surface Oncology, Inc. Announces Preclinical Data on SRF388

New 90-day high: €6.05

New 90-day high - €5.95

Earnings released

Surface Oncology, Inc.(NasdaqGM:SURF) dropped from Russell Microcap Value Index

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Surface Oncology, Inc. Riepilogo dei fondamenti

0.0x

-0.7x

Guadagni e ricavi